Penniston Kristina L, Jones Andrea N, Nakada Stephen Y, Hansen Karen E
Departments of Urology and Medicine, Osteoporosis Clinical Center and Research Program, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
BJU Int. 2009 Nov;104(10):1512-6. doi: 10.1111/j.1464-410X.2009.08559.x. Epub 2009 Apr 15.
To evaluate, in a posthoc analysis of a previous study, whether vitamin D repletion in postmenopausal women with insufficient vitamin D increases urinary calcium excretion, as vitamin D therapy might contribute to hypercalciuria and calcium stones in susceptible individuals, and the effect of vitamin D on the risk of urolithiasis warrants attention.
We recruited 18 women at > or =5 years after menopause who had vitamin D insufficiency (serum 25(OH)-vitamin D, 16-24 mg/dL). We excluded women with a history of urolithiasis and kidney disease. Women had one calcium absorption study when vitamin D-insufficient, received vitamin D therapy, and completed a second calcium absorption study when vitamin D-replete. We fed subjects meals that mirrored the nutrient composition from self-reported 7-day diet diaries. To measure calcium absorption, we collected urine for 24 h during both visits.
We achieved vitamin D repletion in all women (25(OH)-vitamin D before and after treatment, 22 and 63 mg/dL, respectively; P < 0.001). The mean calcium intake was 832 mg/day. Residual urine specimens were available for 16 women, allowing a measurement of 24-h urinary calcium. Calcium excretion did not change after vitamin D therapy (212 before vs 195 mg/day after; P = 0.60). Of four women with hypercalciuria (>247 mg/day), calcium excretion decreased in three (377-312 mg/day, not significant).
Vitamin D supplementation did not increase the urinary calcium excretion in healthy postmenopausal women. Many stone formers are at risk of premature bone loss, vitamin D insufficiency, or both. Based on the present results we suggest a study of patients with hypercalciuria and nephrolithiasis to determine the risks of vitamin D therapy.
在一项既往研究的事后分析中,评估维生素D水平不足的绝经后女性补充维生素D是否会增加尿钙排泄,因为维生素D治疗可能会导致易感个体出现高钙尿症和钙结石,且维生素D对尿石症风险的影响值得关注。
我们招募了18名绝经≥5年且维生素D水平不足(血清25(OH)-维生素D为16 - 24 mg/dL)的女性。我们排除了有尿石症和肾脏疾病史的女性。这些女性在维生素D水平不足时进行了一项钙吸收研究,接受维生素D治疗,在维生素D补充充足时完成了第二项钙吸收研究。我们为受试者提供的饮食与根据自我报告的7天饮食日记得出的营养成分相符。为测量钙吸收情况,我们在两次访视期间均收集了24小时尿液。
所有女性均实现了维生素D补充充足(治疗前后25(OH)-维生素D分别为22和63 mg/dL;P < 0.001)。平均钙摄入量为832 mg/天。16名女性有剩余尿液标本,可用于测量24小时尿钙。维生素D治疗后钙排泄未发生变化(治疗前为212 mg/天,治疗后为195 mg/天;P = 0.60)。在4名高钙尿症(>247 mg/天)女性中,3名女性的钙排泄量下降(从377降至312 mg/天,差异无统计学意义)。
补充维生素D未增加健康绝经后女性的尿钙排泄。许多结石形成者有过早骨质流失、维生素D水平不足或两者兼有的风险。基于目前的结果,我们建议对高钙尿症和肾结石患者进行研究,以确定维生素D治疗的风险。